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Abstract
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Studies of adults with attention-deficit/hyperactivity disorder (ADHD) have suggested that they
have deficient response inhibition, but findings concerning the neural correlates of inhibition in
this patient population are inconsistent. We used the Stop-Signal task and functional magnetic
resonance imaging (fMRI) to compare neural activation associated with response inhibition
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between adults with ADHD (N = 35) and healthy comparison subjects (N = 62), and in follow-up
tests to examine the effect of current medication use and symptom severity. There were no
differences in Stop-Signal task performance or neural activation between ADHD and control
participants. Among the ADHD participants, however, significant differences were associated
with current medication, with individuals taking psychostimulants (N = 25) showing less stoppingrelated activation than those not currently receiving psychostimulant medication (N = 10). Followup analyses suggested that this difference in activation was independent of symptom severity.
These results provide evidence that deficits in inhibition-related neural activation persist in a
subset of adult ADHD individuals, namely those individuals currently taking psychostimulants.
These findings help to explain some of the disparities in the literature, and advance our
understanding of why deficits in response inhibition are more variable in adult, as compared with
child and adolescent, ADHD patients.

Keywords
Inhibitory control; Hyperactivity; Psychostimulants; Functional magnetic resonance imaging
(fMRI); Adults; Stop-Signal task
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1. Introduction
Attention-deficit/hyperactivity disorder (ADHD), which is characterized by ageinappropriate symptoms of inattention, impulsivity and hyperactivity, is the most prevalent
psychiatric disorder of childhood. ADHD may continue into adulthood, with reports of
symptom persistence in as many as 65% of cases (Mannuzza et al., 2003). Compared with
controls, children with ADHD exhibit hypoactivation in frontoparietal and attention
networks involved in executive function, but hyperactivation across large-scale networks,
including the default-mode network, and somatomotor and visual networks (Cortese et al.,
2012). Investigations in adults with ADHD are needed to clarify the basis of deficits that
persist through the course of the disorder.
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Deficient response inhibition, or the ability to suppress a prepotent or habitual response, has
been proposed as a central feature of ADHD (Barkley, 2005). Findings obtained with
functional magnetic resonance imaging (fMRI) suggest that deficient inhibition in ADHD
samples reflects corresponding abnormality in fronto-striatal activation. During response
inhibition, healthy individuals show recruitment of a network of brain regions that includes
the bilateral ventrolateral prefrontal cortex (VLPFC) (encompassing the inferior frontal
cortex (IFC) and insula), the pre-supplementary motor area (SMA)/SMA, medial superior
frontal gyrus (SFG) and cingulate cortex, as well as subcortical regions including the
striatum and thalamus (Aron and Poldrack, 2006; Aron et al., 2007; Swick et al., 2011).
Subjects with ADHD show less activation in these regions compared with controls
(Dickstein et al., 2006; Epstein et al., 2007). In fact, fMRI studies have consistently shown
fronto-striatal hypoactivation in ADHD children and adolescents relative to controls during
tasks requiring not only response inhibition but also those requiring interference inhibition,
attention, and temporal processing, which together have provided considerable support for a
fronto-striatal deficit hypothesis of ADHD (for review, see Cubillo et al. (2012)).
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Only a few fMRI investigations of response inhibition, however, have involved adults with
ADHD, and these studies have provided mixed results. In some cases, adult ADHD patients
showed less activation than controls during response inhibition, including effects in VLPFC,
cingulate, and striatal stopping-related regions (as reviewed by Cubillo et al. (2012) and as
demonstrated in a meta-analysis by Hart et al. (2013)). For example, Mulligan et al. (2011)
reported that a sample of 12 controls recruited a more extensive network of brain regions
during inhibition on a Go/No-Go task as compared with 12 adult ADHD patients, and that
ADHD subjects showed less activation in regions key for response inhibition, including the
right PFC and preSMA. Similarly, Sebastian et al. (2012) reported less activation in an adult
ADHD sample as compared with healthy controls during performance of the Stop-Signal,
Go/No-Go, and Simon interference tasks, with significant effects in the right pallidum and
left IFC in 20 ADHD adults as compared with 24 controls during inhibition of an alreadyinitiated response (Stop-Signal task). Other reports, however, indicated that adults with
ADHD showed no differences in (Carmona et al., 2012) or greater (Dillo et al., 2010; Karch
et al., 2010) fronto-striatal activation during response inhibition as compared to controls. For
example, Dibbets et al. (2009) reported no statistically significant differences in activation in
fronto-striatal regions between 16 adult ADHD males and 13 healthy controls performing a
modified Go/No-Go task. Similarly, while Dillo et al. (2010) found no difference in frontocingulo-striatal activity between 15 adult ADHD and 15 healthy control individuals
performing a Go/No-Go task, they did find increased activation in parietal regions. The
greater activation in parietal (Dillo et al., 2010) and cerebellar (Cubillo et al., 2012) regions
during response inhibition by ADHD patients has been interpreted as reflecting the
engagement of compensatory attentional processes. A number of factors may account for
these discrepancies, including differences in task parameters (specifically differences
between Go/NoGo and Stop-signal tasks), medication status, and symptom severity, as well
as small sample size.
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In an attempt to address these limitations in the literature, we examined differences in task
performance and associated patterns of neural activation, as measured using fMRI, in a
relatively large sample of adult participants with ADHD, as compared to controls, using a
tracking version of the Stop-signal task. We hypothesized that adults with ADHD would
exhibit less activation in stopping-related regions than would controls, and we conducted
exploratory follow-up analyses to examine potential effects of medication status and
symptom severity.

2. Methods
2.1. Participants
All participants were recruited from the Los Angeles area as part of the Consortium for
Neuropsychiatric Phenomics at UCLA (www.phenomics.ucla.edu), in which they completed
extensive neuropsychological testing (additional details provided in Supplementary
Materials). All candidates were screened by telephone and then in person. Participants were
men or women ages 21-50 years; NIH ethnic category either White, not Hispanic or Latino,
or Hispanic or Latino, of any racial group; primary language (as determined by a verbal
fluency test) either English or Spanish; completed at least 8 years of formal education; had
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no significant medical illness; adequately cooperative to complete assessments; and had
visual acuity 20/60 or better. Urinalysis was used to screen for drugs of abuse (cannabis,
amphetamine, opioids, cocaine, benzodiazepines), and participants were excluded if results
were positive. Additional exclusion criteria for participants in the imaging portion of the
study were left-handedness, pregnancy, history of head injury with loss of consciousness or
cognitive sequelae, or other contraindications to scanning (e.g., claustrophobia, metal in
body).
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After receiving a verbal explanation of the study, participants gave written informed consent
following procedures approved by the Institutional Review Boards at UCLA and the
LACDMH. All subjects underwent a semi-structured assessment with the Structured
Clinical Interview for the Diagnostic and Statistics Manual of Mental Disorders, Fourth
Edition (DSM-IV) (SCID-I; (First MB, 2004)), supplemented for ADHD diagnoses with the
Adult ADHD Interview (a structured interview form derived from the Kiddie Schedule for
Affective Disorders and Schizophrenia, Present and Lifetime Version (KSADS-PL)
(Kaufman et al., 1997)), in order to enable a more detailed characterization of lifetime
history of ADHD in adults. For the purpose of this investigation, participants were excluded
for lifetime diagnoses of schizophrenia or other psychotic disorders, bipolar I or II disorder;
or current major depressive disorder, suicidality, anxiety disorder (obsessive-compulsive
disorder, panic disorder, generalized anxiety disorder, post-traumatic stress disorder), or
substance abuse/dependence other than nicotine dependence (which was allowed). Stable
medications were permitted in ADHD participants (discussed below); any self-reported
psychoactive medication use by controls was an exclusion factor. Symptom severity in
patients was assessed with the Adult ADHD Clinical Diagnostic Scale (ACDS), which
provides a quantitative assessment of how current Inattention and Hyperactivity symptoms
impact patient functioning (Goodman, 2009; Kessler et al., 2010).
2.2 Procedure
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Participants completed a tracking version of the Stop-Signal task, which enabled isolation of
activation associated with the inhibition of an already-initiated motor response, and
calculation of an individualized measure of inhibitory control (Stop-Signal reaction time,
SSRT). On the testing day, participants first received training on the Stop-Signal task in the
form of one initial demonstration, before completing two experimental runs (one run outside
of the scanner and one while inside of the scanner). A complete description of the fMRI
acquisition and preprocessing steps is presented in Supplementary Materials.
2.2.1 Stop-Signal task—Participants were instructed to respond quickly when a “go”
stimulus was presented on the computer screen, except on the subset of trials where the “go”
stimulus was paired with a “stop” signal (Fig. 1). Specifically, participants were shown a
series of go stimuli (left- and right-wards pointing arrows), to which participants were told
to respond with left and right button presses, respectively (Go trials). On a subset of trials
(25%), a stop signal (a 500-Hz tone presented through headphones) was presented a short
delay after the go stimulus appeared and lasted for 250 ms (Stop trials). Participants were
instructed to respond as quickly and accurately as possible on all trials, but to withhold their
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response on Stop trials (on trials with the tone). They also were instructed that stopping and
going were equally important.
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On Stop trials, the delay of the onset of the stop signal, or stop-signal delay (SSD), was
varied, such that it was increased after the participant successfully inhibited in response to a
stop-signal (making the next stop trial more difficult), and decreased after the participant
failed to inhibit in response to a stop-signal (making the next stop trial less difficult). Each
SSD increase or decrease was in 50-ms intervals. The SSD values were drawn from two
interleaved staircases per block, resulting in 16 trials from each staircase for a total of 32
Stop trials per block. In the first task run completed outside of the scanner, SSD values
started at 250 and 350 ms for staircase 1 and 2, respectively. At the end of the behavioral
run, the last SSD time from each staircase was then carried over to be the initial SSD for the
scan run. This one-up/one-down tracking procedure ensured that subjects successfully
inhibited on approximately 50% of inhibition trials. Also as a result, difficulty level is
individualized across subjects and both behavioral performance and numbers of successful
stop trials are equated across subjects.
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Each experiment run contained 128 trials, 96 of which were Go trials and 32 of which were
Stop trials, each presented randomly. All trials were preceded by a 500 ms fixation cross in
the center of the screen, then each trial began with the appearance of an arrow and ended
after 1000 ms, followed by the null period. Jittered null events separated every trial (with a
blank screen), with the duration of null events sampled from an exponential distribution
(null events ranged from 0.5 to 4 s, with a mean of 1 s). Stimulus presentation and timing of
all stimuli and response events were achieved using Matlab (Mathworks) and the
Psychtoolbox (www.psychtoolbox.org, Brainard, 1997) on an Apple Powerbook. For the
experiment run administered in the scanner, each participant viewed the task through MRIcompatible goggles, responded with his or her right hand on an MR-compatible button box
in the scanner.
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2.2.2 SSRT calculation—Stop-signal task data were analyzed following the race-model
(Logan and Cowan, 1984), as has been previously reported (Congdon et al., 2010; Congdon
et al., 2012), in order to estimate SSRT, our primary measure of inhibitory control. The
mean and standard deviation of reaction time (RT) on Go trials were calculated only for Go
trials in which participants correctly responded. Stop successful trials included only Stop
trials on which participants successfully inhibited a response, and Stop unsuccessful trials
included only Stop trials on which participants responded. Average SSD was calculated
from SSD values across both staircases. SSRT was estimated using the quantile method,
which does not require an assumption of 50% inhibition (Band et al., 2003). In order to
calculate SSRT according to this method, all RTs on Go trials were arranged in ascending
order, and the RT corresponding to the proportion of failed inhibition was selected. The
average SSD was then subtracted from this quantile RT, providing an estimate of SSRT,
with longer SSRT values reflecting poorer inhibitory control and shorter SSRT values
reflecting better inhibitory control.
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2.3. Behavioral data analysis
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In addition to SSRT, we also examined mean and standard deviation of RT on Go trials,
percent inhibition on Stop trials, and percent correct on Go trials. The distribution of each
variable was inspected prior to analysis to ensure normality and, in the case of percent
accuracy on Go trials, a square root transformation was made. All behavioral analyses were
performed using R statistical software (R 2.10.1) (http://www.r-project.org).
First, multiple linear regression models were used to test the relationship between Stopsignal task performance and demographics, including age, gender, education (defined by
years of school completed), ethnicity (Hispanic/Latino vs. not Hispanic/Latino), and primary
language (English vs. Spanish). Second, one-way analyses of covariance models were used
to examine differences in performance as a function of diagnostic status (control vs.
ADHD), while controlling for demographic measures. Then, patients were grouped
according to self-reported current psychostimulant use and follow-up tests were conducted
to compare these subgroups of participants in symptom severity and performance.
2.4. fMRI data analysis
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Analyses were performed using tools from the FMRIB software library (Smith et al., 2004),
and preprocessing steps are described in Supplementary Materials. For each subject,
StopInhibit-Go and StopRespond-StopInhibit contrasts were computed, and the output from
the subject-specific analyses was then analyzed using a mixed-effects model with FLAME
for between-group comparisons. All group-level statistics images were thresholded with a
cluster-forming threshold of z > 2.3 and a cluster probability of p < 0.05, corrected for
whole-brain multiple comparisons using Gaussian random field theory. Brain regions were
identified using the Harvard-Oxford cortical and subcortical probabilistic atlases (Desikan et
al., 2006) (http://www.cma.mgh.harvard.edu/fsl_atlas.html), and all activations are reported
in MNI coordinates. For reporting of clusters, we used the cluster command in FSL.
Anatomical localization within each cluster was obtained by searching within maximum
likelihood regions from the FSL Harvard-Oxford probabilistic atlas to obtain the maximum
z-statistic and MNI coordinates within each anatomical region contained within a cluster.
For visualization of results, statistical maps were projected onto an average cortical surface
with the use of multifiducial mapping using CARET software (Van Essen, 2005) (http://
brainvis.wustl.edu/wiki/index.php/Caret:Download).
Similar to behavioral analyses, in order to test the effect of psychostimulant medication
status and symptom severity, a whole-brain regression analysis of data from all ADHD
participants was conducted, including psychostimulant status (with ADHD participants
coded as either On or Off psychostimulants), ACDS Inattention severity scores, and ACDS
Hyperactivity severity scores, as covariates of interest. This allowed for examination of the
relationship between activation and current symptoms, while controlling for current
psychostimulant use, and vice versa. We conducted two follow-up tests comparing controls
to ADHD participants On psychostimulants and controls to ADHD participants Off
psychostimulants on our primary contrast of interest. Final follow-up analyses were
conducted after removing ADHD participants taking any medication other than
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psychostimulants (results presented in Supplementary Materials), and to compare males and
female ADHD participants.
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3. Results
Our final analyses are based on data from 97 subjects with complete, usable Stop-signal
fMRI data, including data from 62 healthy participants and 35 adult participants with
ADHD. See Fig. 2 for an illustration of subjects excluded at various stages of analysis.
There was no difference in any of our demographic measures between healthy participants
and adult ADHD participants.

NIH-PA Author Manuscript

Stable medications were permitted in ADHD participants; psychostimulants were used most
often, with 10 of 35 (29%) participants reporting psychostimulant use (Table 1).
Psychostimulant medications taken included preparations containing amphetamine (Adderall
XR®, amphetamine and dextroamphetamine mixed salts; or dextroamphetamine sulfate,
prescribed either as a generic formulation or as Dexedrine®), lisdexamfetamine dimesylate
(Vyvance®), an amphetamine prodrug) or methylphenidate (Concerta® or Metadate™, both
extended-release preparations). To examine the potential effects of current medication use,
analyses were conducted comparing ADHD participants who were taking a stable dose of
psychostimulant medication with those who were not.
3.1. Behavioral results
Behavioral data collected during performance of the Stop-Signal task from all control and
ADHD participants included in the present analysis (N = 97) are presented in Table 1;
ADHD participants are presented together, as well as separated according to current
psychostimulant medication use. Multiple linear regression analyses revealed significant
relationships between age and SSRT (β = 1.40, 95% confidence interval (CI), 0.10, 2.70, p =
0.04), and age and mean RT on Go trials (β = 2.81, 95% CI, 0.60, 5.01, p = 0.01), but no
significant relationships between task performance and gender, ethnicity, education or
language.
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When controlling for demographic measures, there were no significant differences between
controls and adult ADHD participants for any measure of performance. As shown in Table
1, although the mean SSRT was longer in the ADHD group than in controls (d = 0.21),
suggesting poorer inhibitory control, this difference was not significant. These results
suggest comparable performance between healthy controls and adult ADHD participants.
Within the ADHD sample, there was no difference in Stop-Signal task performance between
ADHD participants On (N = 25) vs. Off (N = 10) psychostimulant medication, and there
were no differences between these subgroups in symptom severity, for either the ACDS
Inattention or Hyperactivity symptom scores (p > 0.05).
3.2. fMRI results
3.2.1 Inhibition-related activation—Our primary contrast of interest was StopInhibitGo, which isolates successful stopping-related activation. We conducted a two-sample
comparison of the StopInhibit-Go contrast in order to identify group differences in stopping-
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related activation; there was no significant difference in activation between controls and
adult ADHD participants, in either direction. Similarly, there was no significant difference
between controls and ADHD participants, in either direction, when examining activation
isolated with the StopRespond-StopInhibit contrast, which identified brain regions with
greater activation during inhibition failures as compared to successful inhibition trials
between groups.
For illustration, whole-brain activation maps are presented for each group separately (with
details provided in Table 2), with Fig. 3A representing controls and Fig. 3B the ADHD
sample. Both groups show activation in the set of regions commonly engaged during SSTrelated inhibition, including bilateral VLPFC, striatum, thalamus, and a cluster spreading
through the preSMA/SMA, SFG and cingulate, as well as additional posterior parietal
regions. Although the activation seen in the control sample (Fig. 3A) appeared more robust
and extensive than in the ADHD sample (Fig. 3B), this apparent difference was not
statistically confirmed.
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3.2.2 Effect of symptom severity and medication on inhibition-related
activation—In order to examine the relationship between stopping-related activation and
current symptom severity, in follow-up analyses we added current Inattention and
Hyperactivity scores, along with current psychostimulant use, to a regression model, which
tests the relationship between stopping-related activation and symptom severity while
controlling for psychostimulant use, and vice versa. While there was no correlation between
stopping-related activation and Inattention symptom scores, Hyperactivity symptom scores
were significantly positively correlated with activation in a number of regions, including the
right SFG, MFG, and paracingulate gyrus, right anterior frontal pole, left middle temporal
gyrus, and left supramarginal gyrus (Fig. 4A), while controlling for psychostimulant use.
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There was a significant difference in stopping-related activation as a function of current
psychostimulant medication use, while controlling for either Inattention or Hyperactivity
scores. ADHD participants not currently taking psychostimulants had significantly greater
activation in the right IFC extending up through the precentral gyrus and down through the
insula, as well as the bilateral supramarginal and angular gyri as compared to ADHD
participants currently taking psychostimulants (Fig. 4B, Table 3). There was no greater
activation in ADHD participants taking, as compared to those not taking, psychostimulants.
To further examine differences in stopping-related activation as a function of
psychostimulant status, we conducted two follow-up tests. Controls showed significantly
greater activation in a number of key stopping-related regions as compared to ADHD
participants taking psychostimulants. These included the bilateral VLPFC, the preSMA
extending through the paracingulate gyrus, and bilateral supramarginal and angular gyri
(Fig. 4C, Table 3). In contrast, there was no difference in activation between controls and
ADHD participants not taking psychostimulants.
To summarize, overall ADHD participants engaged a set of brain regions commonly
recruited during response inhibition. Within the ADHD sample, participants not currently
taking psychostimulants showed more activation in a subset of key response inhibition-
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related regions, whereas those participants with more severe symptoms of Hyperactivity,
whether on or off psychostimulant medication, showed greater activation in additional right
frontal, temporal and parietal regions. To further illustrate these differences in patterns of
activation, the 1) group mean of the ADHD participants (red), 2) the difference between
participants not currently taking vs. currently taking psychostimulants (blue) and 3) the
positive correlation with Hyperactivity scores (yellow) are overlaid on a single image in
Figure 4D. While not a statistical comparison, this illustrates where the separate contrasts
differ; there is more overlap between the group mean (red) and the difference as a function
of psychostimulant use (blue) than overlap between the group mean (red) and the correlation
with Hyperactivity symptoms (yellow), suggesting that the medication effect is specific to
response inhibition-related brain activation, whereas – independent of this medication effect
– participants suffering from more severe Hyperactivity symptoms recruit additional regions
when needing to inhibit a prepotent response.
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3.2.3 Ruling out additional medication on inhibition-related activation—As
eight ADHD participants reported taking additional medications (including antidepressants,
antipsychotics, an anticonvulsant-mood stabilizer, and hormone medication), to rule out any
effect of additional medication, follow-up tests excluding these participants were conducted.
Of those ADHD participants not currently taking any medication, we do not know the
duration of time off medication.
Of the 10 ADHD participants who were taking psychostimulants, four reported current use
of an additional medication, and four of the 25 ADHD participants who were not taking
psychostimulants reported current use of a medication other than psychostimulants. We reran the primary analyses excluding these eight ADHD participants, and the results did not
change except in two instances. First, the positive correlation between Hyperactivity
symptoms and stopping-related activation was no longer significant; second, the difference
between control and ADHD participants taking psychostimulants was no longer significant.
In addition, while the difference between ADHD participants not taking psychostimulants
and those who were taking psychostimulants was maintained, it was restricted to the right
supramarginal gyrus in the smaller sample.
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3.2.4 Gender differences on inhibition-related activation in ADHD adult
participants—There were no significant differences in stopping-related activation when
comparing male and female ADHD participants.

4. Discussion
We examined the pattern of neural activation associated with response inhibition in a sample
of 35 adult individuals with ADHD, using the Stop-Signal task, a task requiring participants
to inhibit an already-initiated response. There were no differences in SSRT or neural
activation between adults with ADHD and healthy controls. However, in follow-up tests,
when ADHD participants were stratified according to current psychostimulant medication
use, significant differences in stopping-related neural activation that were not accounted for
by differences in symptom severity were observed between participants taking
psychostimulants and those who were not. Compared with controls and ADHD participants
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not taking psychostimulant medication, adult ADHD participants currently taking
psychostimulants showed less activation in key stopping-related regions. Independent of
this, there was a positive relationship between Hyperactivity symptoms and activation in
cortical regions outside of the stopping-related network, suggesting that additional regions
are recruited in order to achieve comparable inhibition. Thus, both symptom severity and
current psychostimulant medication seem to be associated with the degree of response
inhibition-related activity within this heterogeneous adult ADHD sample. These findings
may help to account for some of the disparities in the existing literature.
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Although a deficit in response inhibition is thought to be central to ADHD, much of the
relevant literature concerns children and adolescents. Several meta-analyses assessing
response inhibition using behavioral assays (Stop-Signal or Go/No-Go tasks) provide
convergent evidence for a modest effect size of deficient response inhibition in ADHD, with
some evidence that inhibitory deficits persist in adulthood. The most comprehensive of these
meta-analyses, focused on SSRT, involved 68 studies of both adults and children, and a
weighted mean effect size of 0.62 was reported (Lipszyc and Schachar, 2010). While effect
sizes in adult ADHD samples were smaller, age was not a significant moderator of SSRT
effect size across all samples. In contrast, we observed no significant differences in SSRT
between ADHD participants and controls, a finding that may reflect our recruitment of
adults only over the age of 21, features of our inclusion/exclusion criteria, or inclusion of
only ADHD participants with sufficient inhibitory control to complete multiple testing
sessions. An examination of the mean SSRT in our sample of 35 ADHD participants
(198.85) in comparison to the weighted mean SSRT in adult ADHD samples (240.97)
reported in a previous meta-analysis (Lijffijt et al., 2005) supports the latter explanation.
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There are a number of factors contributing to mixed findings in fMRI studies of response
inhibition, including small sample sizes. One of the most comprehensive meta-analyses of
fMRI studies in ADHD (Cortese et al., 2012) identified just 16 studies that included adult
ADHD patients; by our count, only five of these studies included tasks assessing response
inhibition (with ADHD sample sizes varying from 8 to 23) (Banich et al., 2009; Cubillo et
al., 2010; Dibbets et al., 2009; Dillo et al., 2010; Karch et al., 2010). A more recent metaanalysis (Hart et al., 2013) included just one additional adult sample investigating motor
response inhibition (Kooistra et al., 2010). In our review of the literature, we have identified
a total of 10 studies that have investigated neural correlates of response inhibition using
either a Go/NoGo or Stop-Signal task and fMRI in adult ADHD participants (Carmona et
al., 2012; Cubillo et al., 2010; Dibbets et al., 2009; Epstein et al., 2007; Karch et al., 2010;
Kooistra et al., 2010; Mulligan et al., 2011; Schneider et al., 2010; Sebastian et al., 2012).
We have summarized these 10 studies in Table 4 in order to highlight differences between
them, and to compare their results with those presented here. Some of the differences across
studies, which may help to explain discrepancies in results, include inconsistencies in task
paradigms, analysis methods, and sample composition.
While Stop-Signal and Go/No-Go tasks are the most commonly employed measures of
response inhibition, and contribute to the same underlying “prepotent response inhibition”
construct (Aichert et al., 2012), the Stop-Signal task measures the ability to inhibit or cancel
a response that has already been initiated, whereas the Go/No-Go task measures the ability
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to withhold a response (Schachar et al., 2007), and a quantitative meta-analysis has shown
that Stop-Signal and Go/No-Go tasks engage overlapping but distinct brain regions (Swick
et al., 2011). As these different task demands may be differentially sensitive to ADHD and
corresponding neural disturbances, the use of variable tasks across studies potentially
contributes to differences in reported findings, as is clear when comparing across studies
listed in Table 4. For example, the following three studies have used an event-related Go/
NoGo design similar enough for comparison: 1) Carmona et al. (2012) conducted a primary
ROI-based analysis in 19 medication-naïve ADHD males and found no difference in IFG
(and exploratory whole-brain analyses) as compared with controls, 2) Epstein et al. (2007)
conducted a region-of-interest based analysis in nine ADHD males and females with a mix
of medication histories and reported less activation in bilateral IFG and left caudate in the
ADHD participants as compared with controls; and 3) (Sebastian et al., 2012) found less
activation in the right caudate in 20 medication-naïve ADHD male and female participants
as compared with controls. While the majority of these studies report less activation in
stopping-related regions in ADHD adult participants as compared to controls, each study
continues to differ in additional factors, including sample composition and analysis methods,
which may account for the reported findings. Overall, there are still too few studies
investigating neural correlates of response inhibition, using either the Go/NoGo or StopSignal tasks, to draw conclusions about consistent patterns of inhibition-related activation in
adult ADHD participants.
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Small sample size has also prevented a complete characterization of how symptom severity
or medication affects inhibition-related activation. This is clearly reflected in three recent
meta-analyses of the ADHD fMRI literature. While Cortese et al. (2012) report a pattern of
ADHD-related hypoactivation in fronto-striatal regions when collapsing across age groups
and tasks, the small sample sizes among the included studies could not support contrasts
between ages, task types, medication history, or psychiatric comorbidity. Indeed, as the
authors report, there were too few published adult ADHD studies using response inhibition
tasks to compare against studies in children and adolescents, despite the large body of
literature demonstrating a central deficit in younger samples. More recently, Hart et al.
(2013) directly investigated age effects by conducting a whole-brain meta-analysis of
published data and found that the pattern of differences between patients and controls
differed slightly as a function of age, with ADHD children showing less activation in the left
putamen, right caudate, SMA and ACC relative to controls, and ADHD adults showing less
activation in the right IFC and thalamus relative to controls. Furthermore, while they
reported an effect of long-term medication use on attention-related neural activation in their
meta-regression analysis, they reported no effect of long-term medication use on inhibitionrelated activation. These negative findings may be explained by a third recent meta-analysis
conducted: while Rubia et al. (2013) were able to conduct a meta-analysis on the effect of
psychostimulant function on brain activation in children and adolescents with ADHD, they
were unable to identify any studies with adult participants that met their inclusion criteria,
which highlights the relative lack of information about medication effects on inhibitionrelated activation in adult ADHD. Thus, although such meta-analyses are able to provide
convergent evidence of an inhibition-related deficit in neural activation in adult ADHD
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We attempted to examine differences as a function of psychostimulant medication status in
exploratory follow-up analyses and, although our results suggest that differences in
medication status may contribute to discrepant findings in the literature on adult ADHD
participants, our findings are unexpected. We found less stopping-related activation in 10
ADHD adult participants currently taking psychostimulants as compared to 25 ADHD
participants not currently taking psychostimulants. This is in contrast to the majority of
studies, which report an increase in neural activation following psychostimulant
administration in ADHD youth (Vaidya et al., 1998; Shafritz et al., 2004; Epstein et al.,
2007; Prehn-Kristensen et al., 2011; Rubia et al., 2011a; Rubia et al., 2011b). Long-term
medication use is thought to normalize an underactive stopping-related response in ADHD
youth (Rubia et al., 2013; Schweren et al., 2013) and this has been demonstrated in other
domains, including attention-related (Hart et al., 2013) and timing-related (Hart et al., 2012)
neural activation. However, as illustrated by a recent meta-analysis, there are insufficient
data on the long-term effect of psychostimulants on stopping-related neural activation in
adult ADHD participants (Rubia et al., 2013). Our findings of less stopping-related
activation in ADHD participants currently taking psychostimulants are in line with previous
reports of the effects of medication exposure on inhibition-related activation in healthy
adults (Chamberlain et al., 2009; Costa et al., 2012), and with a report of a decrease in
fronto-cingulate activation during Go/No-Go task performance in ADHD adolescents treated
with methylphenidate (Schulz et al., 2012). Notably, in a randomized treatment study,
Schulz et al. (2012) reported that while symptom improvements following methylphenidate
(a stimulant) and atomoxetine (a non-stimulant) administration were associated with
decreased activation in the bilateral motor cortex, symptom improvement following
methylphenidate administration was associated with a decrease in right IFC, ACC/SMA,
and posterior cingulate activation while symptom improvement following atomoxetine
administration was associated with an increase in these same regions in ADHD youth.
However, our cross-sectional results cannot entirely address medication history, illness
duration, or illness severity, or the interaction of these factors with developmental processes;
less activation as a function of psychostimulant use and/or symptom severity on the
background of ADHD that persists in adulthood may not have the same functional
implications that it does in ADHD youth. It is clear that additional research is warranted to
compare the effects of long-term psychostimulant medication on stopping-related neural
activation in adult ADHD participants.
There are additional factors that may explain discrepant findings across fMRI studies of
response inhibition in adult ADHD participants, which may also account for our unexpected
findings of less activation in ADHD adult participants currently taking psychostimulants as
compared with those not currently taking psychostimulants. The heterogeneity of the adult
ADHD population is reflected in the varying sample compositions, as reflected in Table 4:
gender distribution, ADHD subtype, current medication status as well as medication history,
and illness severity (indexed by the method of patient ascertainment) have varied across
studies. While we did not find any differences in stopping-related activation as a function of
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gender in additional follow-up analyses, we did not have enough power to conduct
additional analyses examining differences between groups divided by gender and
medication status. When we did attempt to rule out additional medication effects on
inhibition-related activation, our findings changed in the direction of no longer being
significant, which is likely the result of being underpowered to test differences between
small follow-up samples. We can speculate further that individual differences in
dopaminergic function contribute to variations in the effect of psychostimulant medication
on stopping-related activation in ADHD (Ghahremani et al., 2012), and that this interaction
may vary as a function of age, given that long-term psychostimulants induce changes in
brain structure (Shaw et al., 2009) and function (Rubia et al., 2013). Indeed, the effect of
medication history may be a critical factor in explaining mixed findings. While we found no
difference in activation between 35 adult male and female ADHD participants with a mix of
medication histories and current use, as compared to controls, the two published Stop-signal
studies report less activation in medication naïve adults: 1) Cubillo et al. (2010) reported less
activation in the bilateral inferior prefrontal cortex, caudate and thalamus in 11 medicationnaïve ADHD male adults; and 2) Sebastian et al. (2012) reported less activation in the right
pallidum and (at a reduced threshold) the left IFG in 20 medication naïve adult male and
female ADHD participants. Motivated by the high rates of ADHD persistence in adulthood,
longitudinal investigations are needed to address the influence of psychostimulant use – over
time – on the neural correlates of response inhibition in adult ADHD.
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Independent of current psychostimulant use, we also found a positive association between
Hyperactivity symptoms, as measured with the ACDS, and brain activation in a number of
regions, including the right frontal pole, right SFG, paracingulate gyrus, in addition to left
temporal and parietal regions. Perhaps not surprisingly, given the variety of task demands
and medication status, studies are mixed in terms of whether they report a positive or
negative association between stopping-related activation and current symptoms. Carmona et
al. (2012) found no association between right IFG activation during inhibition and current
symptoms, while Cubillo et al. (2010) reported a negative association between Attention/
Hyperactivity symptoms and brain activation in extended frontal, parietal, and temporal
regions, as well as in the anterior cingulate, caudate, putamen, thalamus and cerebellum. Our
results also differ somewhat with those of Schneider et al. (2010), who found a negative
association between Hyperactivity scores, as measured with a self-rating scale for ADHD,
and activation in the right SFG, left MFG, left precentral gyrus, and left superior lobe, and a
positive association between Hyperactivity scores and activation in the anterior insula, right
inferior temporal gyrus, and left lingual gyrus. However, their finding of both increased and
decreased activation associated with current Hyperactivity symptoms suggests that, similar
to our results, altered patterns of activation are required in patients with more severe
symptoms. In additional follow-up analyses, when we excluded eight participants taking
medications other than psychostimulants, this positive correlation with Hyperactivity
symptoms was no longer significant, although this is likely due to the resulting loss of
power. We argue that a finding of a positive correlation between activation in these regions
and Hyperactivity scores reflects compensatory activation in those subjects with more severe
symptoms, as these regions tend to fall outside the set of regions significantly active in the
group. This is illustrated in Fig. 4D, where we have overlaid findings demonstrating an
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Although our study represents one of the largest fMRI investigations of Stop-signal related
inhibition in adult ADHD participants, our sample may still be underpowered to detect
subtle differences in performance or activation between adult ADHD participants and
controls, or differences within the ADHD sample. In particular, although we were able to
examine differences with ADHD adult participants as a function of current psychostimulant
use, our finding of less activation in 10 ADHD participants currently taking
psychostimulants as compared to either 25 ADHD participants not currently taking
psychostimulants or 62 controls may be explained by a lack of power to detect activation in
this sample. Second, our sample of ADHD participants is heterogeneous with respect to
treatments received and, as a result, we examined effects of symptom severity and
medication in a series of exploratory follow-up analyses. Although current symptom
severity as measured by the ACDS did not account for differences between ADHD
participants currently taking vs. not currently taking psychostimulants, there may be
additional unmeasured factors that account for these differences in activation amongst
ADHD participants—including long-term medication use. Overall, these results concerning
differences as a function of current psychostimulant use should be considered preliminary
and require replication. Third, we did not find significant differences in Stop-Signal task
performance or stopping-related brain activation between the ADHD and control samples,
despite widespread evidence supporting such a difference. An advantage of the Stop-Signal
task is its ability to isolate neural activation underlying successful response inhibition;
however, the tracking-design titrates the parameters of the task to fit each individual’s level
of inhibitory control, which ensures that all participants inhibit on approximately 50% of
trials. In doing so, the task obscures differences in the number of commission errors that
might otherwise be detected using a non-tracking inhibition task, such as the Go/No-Go
task. An outstanding question is whether these facets of impulsive behavior (inhibitory
control vs. commission errors) are differentially sensitive to adult ADHD pathology.
Randomizing drug-naïve ADHD participants to psychostimulant medication or placebo
treatment conditions and assessing changes in response inhibition, as measured both
behaviorally and with fMRI, using both Stop-Signal and Go/No-Go tasks, would directly
address these outstanding questions, and help to elucidate whether deficient response
inhibition-related neural activation is an age-independent marker of ADHD pathology.
The results contribute to an understanding of neuroanatomical alterations present in adult
ADHD. While deficits in response inhibition and stopping-related hypoactivation are widely
reported in samples of children and adolescents with ADHD, the findings in samples of
adult ADHD participants are inconsistent. We report no differences in Stop-Signal task
performance or associated neural activation between a relatively large sample of adult
ADHD participants and controls. However, exploratory follow-up analyses reveal that
whether or not adult ADHD participants exhibit less activation in a subset of stoppingrelated regions, as compared with healthy controls, depends on current psychostimulant use.
According to our follow-up tests, this effect of psychostimulant medication use was not
solely driven by current symptom severity. Given the sample size, however, our results must
be considered preliminary and follow-up studies are warranted. Our results help to explain
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some of the discrepancies in the literature and lend support to the notion that these deficits
persist into adulthood in a subset of individuals with ADHD. Further research is needed to
understand why those individuals currently taking psychostimulants show these persistent
deficits.
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Schematic of the Stop-Signal task. Participants were shown a series of go stimuli (left- and right-wards pointing arrows), to
which participants were told to respond with left and right button presses, respectively (Go trials); on a subset of trials, a stopsignal (a 500-Hz tone presented through headphones) was presented at a variable delay after the onset of the go stimulus
(duration indicated by stop-signal delay (SSD)) and lasted for 250 ms (Stop trials), indicating that participants should withhold
the go response.
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Fig. 2.

Consort diagram of data collection and exclusion.
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Fig. 3.
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Separate group maps of StopInhibit-Go activation. Stopping-related activation in controls (A) and adult ADHD (B) groups
alone. Statistical maps are corrected for whole-brain multiple comparisons and were projected onto an average cortical surface
using CARET (R = Right). The color represents the z-score.
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Fig. 4.
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Differences in StopInhibit-Go activation as a function of symptom severity and medication use. While controlling for
psychostimulant use, positive correlation between StopInhibit-Go activation and Hyperactivity symptoms in ADHD participants
alone (A). While controlling for Hyperactivity symptoms, greater stopping-related activation seen in ADHD participants Off vs.
On psychostimulant medication (B) and in controls vs. ADHD participants On psychostimulant medication (C). Multiple
contrasts overlaid on a single image to illustrate overlap (D), with ADHD group mean in red, greater stopping-related activation
seen in ADHD participants Off vs. On psychostimulant medication in blue, and the positive correlation between stoppingrelated activation and Hyperactivity symptoms in yellow. Statistical maps are corrected for whole-brain multiple comparisons
and were projected onto an average cortical surface using CARET; in D, axial slices are included to illustrate the overlap of
activation with coordinated in MNI space (R = Right). The color represents the z-score.
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494.06 (106.06)
111.89 (44.62)
99.18 (1.76)
49.45 (5.70)
NA
NA

Mean Go RT

SD Go RT

Percent correct
responses—Go trials

Percent inhibition—
Stop trials

ACDS Inattention

ACDS Hyperactivity

29.49 (4.49)

33.94 (2.24)

49.20 (8.69)

98.18 (5.46)

109.12(39.73)

500.73 (90.29)

198.85 (65.50)

14.69(1.83)

100%

17%

46%

30.86 (10.01)

ADHD
N = 35
Mean (SD)

29.60 (4.32)

33.88 (2.15)

49.38 (9.46)

97.79 (6.38)

112.28 (42.03)

513.46(100.18)

195.21 (70.80)

14.28 (1.74)

100%

20%

44%

31.24(10.37)

ADHD
No Psychostimulants
N = 25
Mean (SD)

29.20 (5.14)

34.10 (2.56)

48.75 (6.78)

99.17 (1.61)

101.20 (33.98)

468.91 (49.57)

207.95 (52.09)

15.70 (1.70)

100%

10%

50%

29.90 (9.48)

ADHD
Psychostimulants
Used
N = 10
Mean (SD)
b

c
t(14.38) = −0.22,p > 0.05

c

t(14.36) = −0.24,p > 0.05

b
F(l,90) = 0.03,p > 0.05

b

F(l,90) = 1.78,p > 0.05

F(1,90) = 0.10,p 0.05

b

F(l,90) = 0.11,p > 0.05

b

F(1,90) = 1.09, p > 0.05

b

b
t(68.23) = −1.08, p > 0.05

b

χ2(1) = 1.55,p > 0.05

b

χ2(1) = 2.83,p > 0.05

χ2(l) = 0.42,p > 0.05

b

t(64.42) = −0.02, p 0.05

Group Comparisons

c
ADHD participants not currently taking psychostimulant medication (N = 25) vs. ADHD participants currently taking psychostimulant medication (N = 10). ADHD No Psychostimulants = ADHD
participants not currently taking psychostimulant medication; ADHD Psychostimulants Used = ADHD participants currently taking psychostimulant medication. %F = percent of each sample comprised of
women; % Hispanic/Latino = percent of Hispanic/Latino ethnicity vs. not Hispanic/Latino; % English = percent whose primary language is English vs. Spanish; Education = number of school years
competed. SSRT = Stop-signal reaction time; SD = standard deviation. ACDS = ADHD Clinical Diagnostic Scale. Square root transformation of percent correct on Go trials used in ANCOVA, but raw
values presented here. Psychostimulant medications taken included preparations containing amphetamine (Adderall XR®, amphetamine and dextroamphetamine mixed salts; or dextroamphetamine sulfate,
prescribed either as a generic formulation or as Dexedrine®), lisdexamfetamine dimesylate (Vyvance®), an amphetamine prodrug) or methylphenidate (Con certa® or Metadate™, both extended-release
preparations).

Controls (N = 60) vs. all ADHD participants (N = 35).

b

186.38 (52.64)

SSRT

15.10(1.75)

92%

Language(%
English)

Education

35%

Ethnicity (%
Hispanic/Latino)

a
Age
55%

30.82 (8.97)

Variable

Gender (%F)

Controls
N = 62
Mean (SD)

Each sample included participants in the range of 18-50.

a
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Descriptive statistics of Stop-signal task performance in healthy control and adult ADHD samples
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Table 2

Clusters of activation during response inhibition
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Brain region

Hemisphere

Voxels

Max z-stat

X

y

z

R/L

33,539

7.90

64

−16

2

Insula, IFG, frontal orbital cortex,
precentral gyrus

L

1,691

7.20

−32

20

4

Caudate, pallidum, putamen, thalamus

R

784

4.22

12

8

4

Caudate, putamen, thalamus

L

551

4.27

−8

2

−6

Superior temporal gyrus, middle temporal
gyrus, IFC, insula, frontal orbital cortex,
precentral gyrus, MFG, SFG, preSMA,
paracingulate/ACC (R/L), lateral occipital
cortex/occipital pole (R/L), supramarginal
gyrus

R

25,171

8.18

64

−16

2

Superior temporal gyrus, middle temporal
gyrus, insula, frontal orbital cortex,
supramarginal gyrus

L

4,197

7.05

−42

−28

6

R/L

544

3.70

−10

8

−4

Clusters of Stoplnhibit-Go in Controls alone
Superior temporal gyrus, middle temporal
gyrus, IFG (R), insula (R), frontal orbital
cortex (R), precentral gyrus (R), MFG,
SFG, preSMA, paracingulate/ACC,
supramarginal gyms, lateral occipital
cortex/occipital pole

Clusters of Stoplnhibit-Go in ADHD alone

NIH-PA Author Manuscript

Caudate, putamen (L), thalamus (R)

Voxels: number of activated voxels per cluster; z-stat: maximum z-statistic for each cluster; x, y, and z are MNI coordinates for the peak of each
cluster. R = right; L = left; IFG = inferior frontal gyrus; MFG = middle frontal gyrus; SFG = superior frontal gyrus; preSMA = pre-supplementary
motor area; ACC = anterior cingulate cortex.
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Table 3
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Activation differences as a function of psychostimulant medication status and symptom
severity during response inhibition
Brain region

Hemisphere

Voxels

Max z-stat

X

y

z

Clusters of Stoplnhibit-Go activation positively correlated with ACDS Hyperactivity symptoms
a
in ADHD alone
SFG, MFG, paracingulate (R/L)

R

996

4.16

26

24

46

Middle temporal gyrus, planum polare

L

447

3.81

−64

−14

−12

(R/L)

402

3.80

−4

−102

−6

Frontal pole

Occipital pole

R

371

3.15

22

62

−10

Lateral occipital cortex, supramarginal
gyrus, angular gyrus

L

358

3.20

−48

−60

50

Clusters of Stoplnhibit-Go where ADHD Off> On Psychostimulant medication

b

Supramarginal gyrus, angular gyrus

R

1,821

4.45

58

−38

38

IFG, precentral gyrus, insula

R

1,293

4.00

54

14

24

Supramarginal gyrus

L

445

3.72

−60

−38

36
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Clusters of Stoplnhibit-Go where Controls > ADHD On Psychostimulant medication
IFG, insula, frontal orbital cortex

R

1,639

4.31

44

16

−10

R/L

1,314

4.18

−2

8

60

Angular gyrus, supramarginal gyrus

R

1,182

4.25

62

−50

34

Supramarginal gyrus

L

930

4.01

−46

−46

40

preSMA, paracingulate, SFG

Cerebellum

R

893

4.48

34

−56

−34

Precentral gyrus, MFG, IFG

L

752

4.06

−44

−16

66

Frontal pole

L

621

3.99

−42

54

−6

IFG, insula, frontal orbital cortex

L

565

4.31

−46

16

−2

a

Controlling for Inattention symptoms and current psychostimulant use;

b

Controlling for Hyperactivity and Inattention symptoms. Voxels: number of activated voxels per cluster; z-stat: maximum z-statistic for each
cluster; x, y, and z are MNI coordinates for the peak of each cluster. ACDS, Adult ADHD Clinical Diagnostic Scale. R = right; L = left; IFG =
inferior frontal gyrus; preSMA = pre-supplementary motor area; SFG = superior frontal gyrus; MFG = middle frontal gyrus.
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Karch et al.
(2010)

Epstein et
al. (2007)

Dillo et al.
(2010)

Dibbets et
al. (2009)

Cubillo et
al. (2010)

Carmona et
al. (2012)

-

-

11 adult
ADHD (29.00
(1.00))
14 controls
(28.00 (2.00))
16 adult
ADHD (28.90
(6.44))
13 controls
(28.60 (6.45))

14 adult
ADHD (28.10
(NR))
15 controls
(28.80 (NR))

9 adult ADHD
(48.60 (9.00))

-

-

-

-

-

-

-

-

-

8 adult ADHD
(38.30 (7.82))

9 controls
(46.80 (3.90))

-

19 controls
(29.36 (7.84))

-

Males and females

-

All medication free

Males and females

-

Mix of medication
history; washout period
prior to scanning

-

Mix of subtypes

Mix of medication
history; washout 3
weeks prior to scanning

-

Males and females

-

14/16 ADHD subjects
taking psychostimulants

All male

All medication naïve

Mix of ADHD subtypes

All male

-

-

-

-

All ADHD Combined
subtype

All medication naïve

All male

-

Sample composition

19 adult
ADHD (33.58
(10.30))

Sample sizes
(Mean (SD) Age)

Exploratory
whole-brain
analyses

ROI-based
analyses of
the IFG

Fixed-effects
group analyses

Event-related
Go/NoGo task
(NoGo vs. Go trials)

Modified eventrelated Go/NoGo
task ([Voluntary
inhibition vs.
Voluntary selection]

Whole-brain
and ROI-based
analysis

Whole-brain
analyses

Whole-brain
analyses

-

-

Between-group
analyses

ROI-based
analyses of
striatum, frontal
gyri, ACC,
posterior
parietal gyrus,
and cerebellum

Block Go/NoGo task
(NoGo vs. Go
blocks)

Modified eventrelated Go/NoGo
task (correct NoGo
vs. Go trials)

Tracking Stop-signal
task (successful Stop
vs. Go trials)

Event-related
Go/NoGo (NoGo vs.
Go trials)

Response
Inhibition Task
(contrast)

Whole-brain: No differences
in activation

ROI: No difference in IFG
activation

Less activation in medial and
lateral PFC in ADHD subjects
vs. controls

Greater activation in left
inferior parietal lobe and ACC
in ADHD vs. controls

Less activation in bilateral
IFG and left caudate in
ADHD subjects vs. controls
-

-

More ADHD subjects than
controls showed activation in
ACC and parietal ROIs

ADHD group showed
additional activation in
bilateral superior and inferior
parietal lobe and occipital
regions vs. controls
-

-

No differences in activation
between for correct NoGo/Go

Less activation in bilateral
inferior prefrontal cortex,
caudate, and thalamus in ADHD
vs. controls

-

-

Results
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Males and females
8 ADHD subjects in
partial remission

-

12 controls
(29.90 (1.40))

19 adult
ADHD (32.60
(9.40))
17 controls
(29.40 (8.60))

20 adult
ADHD (33.30
(8.90))
24 controls
(30.30 (8.10))

-

-

-

-

-

-

All medication naive

Males and females

All medication naive

Mix of medication
history; washout 48
hours prior to scanning

-

-

All male

-

12 adult
ADHD (31.60
(2.50))

Mix of medication
history; all medication
free

2 ADHD subjects in
partial remission

-

-

-

All male

10 controls
(22.30 (NR))

10 adult
ADHD (21.50
(NR))

-

-

-

8 controls
(37.80 (6.6.1))

-

-

Tracking Stopsignal task
(successful Stop
vs. Go trials)

Event-related Go/
NoGo task (NoGo
vs. Go trials)

Event-related
Go/NoGo task
(NoGo vs. NR)

Event-related
Go/NoGo task
(NoGo vs. baseline
trials)

Modified eventrelated Go/NoGo
task (Fast event
NoGo vs. Go trials;
Slow even NoGo vs.
Go trials)

– [NoGo vs. Go]
trials)

Whole-brain
analyses

Whole-brain
analysis

Whole-brain
and ROI-based
analysis

Whole-brain
analyses

Between-group
analyses

Successful Stop vs. Go trials:
Less activation in the right
pallidum and (at reduced
threshold) left IFG in ADHD
subjects vs. controls

NoGo vs. Go trials: Less
activation in the right caudate
in ADHD subjects vs. controls
-

-

Greater activation in bilateral
fusiform and lingual gyri in
ADHD subjects vs. controls
-

Less activation in bilateral
SFG, right middle and
superior temporal gyri, right
supramarginal gyrus, left
superior parietal lobe, and
right caudate in ADHD
subjects vs. controls
-

Similar regions active in each
group contrast
-

In follow-up ROI analyses,
less activation in right frontal
eye field, right pre-SMA, right
and left inferior parietal lobe,
and left precentral gyrus in
ADHD subjects vs. controls

Slow event NoGo vs. Go:
Greater activation in medial
and lateral PFC, ACC,
posterior cingulate, caudate,
putamen, and thalamus in
ADHD subjects vs. controls
-

-

Fast event NoGo vs. Go:
Greater activation in
supramarginal and ACC in
ADHD subjects vs. controls

-

Results

ROI = region of interest; NR = not reported; IFG = inferior frontal gyrus; ACC = anterior cingulate cortex; PFC = prefrontal cortex; SMA = supplementary motor area; SFG = superior frontal gyrus.

Sebastian et
al. (2012)

Schneider et
al. (2010)

Mulligan et
al. (2011)

Kooistra et
al. (2010)
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Response
Inhibition Task
(contrast)

NIH-PA Author Manuscript
Sample composition

NIH-PA Author Manuscript

Sample sizes
(Mean (SD) Age)
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